<DOC>
	<DOCNO>NCT00997009</DOCNO>
	<brief_summary>This study aim assess activity combination cetuximab ( weekly ) carboplatin + paclitaxel ( every three week ) compare chemotherapy alone term event-free survival ( EFS ) .</brief_summary>
	<brief_title>Study Adding Cetuximab Chemotherapy Treatment Advanced and/or Recurrent Cervical Cancer</brief_title>
	<detailed_description>The poor long-term result standard treatment chemotherapy cervical cancer make research new , beneficial treatment strategy necessary . Cetuximab new type drug block epidermal growth factor receptor ( anti-EFGR ) , show significant activity cancer ( colon , head neck ) expression EGFR high . Cervical cancer cell express EGFR high proportion case , especially recurrent resistant disease . This study evaluate activity addition cetuximab full dose carboplatin paclitaxel .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Advanced and/or metastatic cervical cancer patient untreated fail one previous chemotherapy ( least 6 month progression free interval , without concomitant sequential radiotherapy ) . At baseline , presence least one measurable target lesion ( lesion accurately measure least one dimension i.e . long diameter least 20 mm conventional CT scan least 10 mm spiral CT scan accord RECIST Criteria ) . Not amenable surgery and/or radiotherapy . PS 01 accord ECOG . Age &gt; 18 . Life expectancy least 3 month . Adequate organ function Hematopoietic : Leukocytes &gt; 3,000/mm3 ; Absolute neutrophil count &gt; = 1,500/mm3 ; Platelets count &gt; = 100,000/mm3 ; Hemoglobin &gt; = 9 g/dL Hepatic : AST ALT &lt; = 3 time upper limit normal ( ULN ) * ; Alkaline phosphatase &lt; = 3 time ULN* ; Bilirubin &lt; = 1.5 time ULN * : &lt; = 5 time ULN liver metastases present Renal : Creatinine clearance &gt; = 45 mL/min No invasive malignancy within past 5 year except nonmelanoma skin cancer . All radiology study must perform within 28 day prior randomization . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . Written informed consent . Pregnant ( potentially fertile patient must use contraceptive measure avoid pregnancy least 3 month study participation must negative serum pregnancy test baseline ) . Patients breastfeed treatment 2 month follow end treatment . More one previous chemotherapy line . Active infection require antibiotic . Symptomatic peripheral neuropathy &gt; grade 2 accord CTCAE . Congestive heart failure angina pectoris even medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled high risk hypertension arrhythmia . Known hypersensitivity study drug drug similar chemical structure . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study screen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>EGFR</keyword>
	<keyword>chemotherapy</keyword>
</DOC>